Patents by Inventor John Manfredi

John Manfredi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170050937
    Abstract: Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Application
    Filed: March 25, 2016
    Publication date: February 23, 2017
    Inventors: Sui Xiong Cai, Nilantha Sudath Sirisoma, Azra Pervin, John A. Drewe, Shailaja Kasibhatla, Songchun Jiang, Hong Zhang, Chris Pleiman, Vijay Baichwal, John Manfredi, Leena Bhoite
  • Patent number: 9216966
    Abstract: The present disclosure relates to novel indole and tetrahydroindole core compounds useful for the treatment of disorders associated with a defect in vesicular transport (e.g., axonal transport).
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: December 22, 2015
    Inventor: John Manfredi
  • Publication number: 20130261118
    Abstract: The present disclosure relates to novel indole and tetrahydroindole core compounds useful for the treatment of disorders associated with a defect in vesicular transport (e.g., axonal transport).
    Type: Application
    Filed: March 13, 2013
    Publication date: October 3, 2013
    Inventor: John Manfredi
  • Publication number: 20120225845
    Abstract: The invention provides novel compounds useful for the treatment of disorders associated with a defect in vesicular transport (e.g., axonal transport). The compounds have a substituents chosen from -L-C(?O)OH, -L-CH?CHC(?O)OH, -L-C(?O)NH2, -L-C(?O)NH(C1-3 alkyl), -L-C(?O)N(C1-3 alkyl)2, -L-S(?O)2(C1-3alkyl), -L-S(?O)2NH2, -L-S(?O)2N(C1-3 alkyl)2, -L-S(?O)2NH(C1-3 alkyl), -L-C(?O)NHOH, -L-C(?O)CH2NH2, -L-C(?O)CH2OH, -L-C(?O)CH2SH, -L-C(?O)NHCN, -L-NHC(?O)ORo, -L-C(?O)NHRo, -L-NH(C?O)NHRo, -L-C(?O)N(Ro)2, -L-NH(C?O)N(Ro)2, -L-sulfo, -L-(2,6 difluorophenol), -L-phosphono, and -L-tetrazolyl, where L is a linker.
    Type: Application
    Filed: May 4, 2012
    Publication date: September 6, 2012
    Applicant: Myrexis, Inc.
    Inventors: Christine Klein, Andrew D. Gassman, Leena Bhoite, John Manfredi
  • Publication number: 20120065241
    Abstract: Pyrrole derivatives are disclosed as agents for the treatment and prevention of neuropathies and neurodegenerative diseases characterized by the presence of axonal blockages, impaired axonal transport or impaired trafficking of vesicles in neurons.
    Type: Application
    Filed: November 15, 2011
    Publication date: March 15, 2012
    Applicant: Myrexis, Inc.
    Inventors: Christine Klein, Andrew Gassman, Leena Bhoite, John Manfredi
  • Patent number: 7611854
    Abstract: Yeast cells are engineered to express both a surrogate of a pheromone system protein (e.g., enzymes involved in maturation of ?-factor, transporters of a-factor, pheromone receptors, etc.) and a potential peptide modulator of the surrogate, in such a manner that the inhibition or activation of the surrogate affects a screenable or selectable trait of the yeast cells. Various additional features improve the signal-to-noise ratio of the screening/selection system.
    Type: Grant
    Filed: June 18, 2003
    Date of Patent: November 3, 2009
    Assignee: Cadus Technologies, Inc.
    Inventors: Dana M. Fowlkes, Jim Broach, John Manfredi, Christine Klein, Andrew J. Murphy, Jeremy Paul, Joshua Trueheart
  • Publication number: 20090253768
    Abstract: Pyrrole derivatives are disclosed as agents for the treatment and prevention of neuropathies and neurodegenerative diseases characterized by the presence of axonal blockages, impaired axonal transport or impaired trafficking of vesicles in neurons.
    Type: Application
    Filed: March 9, 2009
    Publication date: October 8, 2009
    Applicant: Myriad Genetics, Incorporated
    Inventors: Christine Klein, Andrew Gassman, Leena Bhoite, John Manfredi
  • Publication number: 20090099179
    Abstract: The invention provides novel compounds useful for the treatment of disorders associated with a defect in vesicular transport (e.g., axonal transport). The compounds have a substituents chosen from -L-C(?O)OH, -L-CH?CHC(?O)OH, -L-C(?O)NH2, -L-C(?O)NH(C1-3 alkyl), -L-C(?O)N(C1-3 alkyl)2, -L-S(?O)2(C1-3alkyl), -L-S(?O)2NH2, -L-S(?O)2N(C1-3 alkyl)2, -L-S(?O)2NH(C1-3 alkyl), -L-C(?O)NHOH, -L-C(?O)CH2NH2, -L-C(?O)CH2OH, -L-C(?O)CH2SH, -L-C(?O)NHCN, -L-NHC(?O)ORo, -L-C(?O)NHRo, -L-NH(C?O)NHRo, -L-C(?O)N(Ro)2, -L-NH(C?O)N(Ro)2, -L-sulfo, -L-(2,6 difluorophenol), -L-phosphono, and -L-tetrazolyl, where L is a linker.
    Type: Application
    Filed: April 4, 2007
    Publication date: April 16, 2009
    Applicant: MYRIAD GENETICS, INCORPORATED
    Inventors: Christine Klein, Andrew D. Gassman, Leena Bhoite, John Manfredi
  • Patent number: 7416881
    Abstract: Yeast cells are engineered to express both a surrogate of a pheromone system protein (e.g., enzymes involved in maturation of ?-factor, transporters of a-factor, pheromone receptors, etc.) and a potential peptide modulator of the surrogate, in such a manner that the inhibition or activation of the surrogate affects a screenable or selectable trait of the yeast cells. Various additional features improve the signal-to-noise ratio of the screening/selection system.
    Type: Grant
    Filed: April 5, 1999
    Date of Patent: August 26, 2008
    Assignee: Cadus Technologies, Inc.
    Inventors: Dana M. Fowlkes, Jim Broach, John Manfredi, Christine Klein, Andrew J. Murphy, Jeremy Paul, Joshua Trueheart
  • Publication number: 20080039479
    Abstract: Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Application
    Filed: July 23, 2007
    Publication date: February 14, 2008
    Applicants: Myriad Genetics, Incorporated, Cytovia, Inc.
    Inventors: Sui Cai, Nilantha Sirisoma, Azra Pervin, John Drewe, Shailaja Kasibhatla, Songchun Jiang, Hong Zhang, Chris Pleiman, Vijay Baichwal, John Manfredi, Leena Bhoite
  • Publication number: 20080032974
    Abstract: Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Application
    Filed: July 17, 2007
    Publication date: February 7, 2008
    Applicants: Myriad Genetics, Incorporated, Cytovia, Inc.
    Inventors: Sui Xiong Cai, Nilantha Sirisoma, Azra Pervin, John Drewe, Shailaja Kasibhatla, Songchun Jiang, Hong Zhang, Chris Pleiman, Vijay Baichwal, John Manfredi, Leena Bhoite
  • Publication number: 20070249601
    Abstract: Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Application
    Filed: March 29, 2007
    Publication date: October 25, 2007
    Applicants: Myriad Genetics, Incorporated, Cytovia, Inc.
    Inventors: Sui Cai, Nilantha Sirisoma, Azra Pervin, John Drewe, Shailaja Kasibhatla, Songchun Jiang, Hong Zhang, Chris Pleiman, Vijay Baichwal, John Manfredi, Leena Bhoite
  • Publication number: 20070244113
    Abstract: Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Application
    Filed: March 1, 2007
    Publication date: October 18, 2007
    Applicants: Myriad Genetics, Incorporated, Cytovia, Inc
    Inventors: Sui Cai, Nilantha Sirisoma, Azra Pervin, John Drewe, Shailaja Kasibhatla, Songchun Jiang, Hong Zhang, Chris Pleiman, Vijay Baichwal, John Manfredi, Leena Bhoite
  • Publication number: 20070244114
    Abstract: Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Application
    Filed: March 13, 2007
    Publication date: October 18, 2007
    Applicants: Myriad Genetics, Incorporated, Cytovia, Inc.
    Inventors: Sui Cai, Nilantha Sirisoma, Azra Pervin, John Drewe, Shailaja Kasibhatla, Songchun Jiang, Hong Zhang, Chris Pleiman, Vijay Baichwal, John Manfredi, Leena Bhoite
  • Publication number: 20070208044
    Abstract: Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Application
    Filed: January 5, 2007
    Publication date: September 6, 2007
    Applicant: Myriad Genetics, Incorporated
    Inventors: Sui Cai, Nilantha Sirisoma, Azra Pervin, John Drewe, Shailaja Kasibhatla, Songchun Jiang, Hong Zhang, Chris Pleiman, Vijay Baichwal, John Manfredi, Leena Bhoite
  • Patent number: 7250263
    Abstract: The present invention makes available a rapid, effective assay for screening and identifying pharmaceutically effective compounds that specifically interact with and modulate the activity of a cellular receptor or ion channel. The subject assay enables rapid screening of large numbers of polypeptides in a library to identifying those polypeptides which induce or antagonize receptor bioactivity. The subject assay is particularly amenable for identifying surrogate ligands for orphan receptors.
    Type: Grant
    Filed: January 5, 2004
    Date of Patent: July 31, 2007
    Assignee: Cadus Technologies, Inc.
    Inventors: Christine A. Klein, Andrew J. M. Murphy, Dana M. Fowlkes, James Broach, John Manfredi, Jeremy Paul, Joshua Trueheart
  • Patent number: 7235648
    Abstract: Yeast cells are engineered to express both a surrogate of a pheromone system protein (e.g., enzymes involved in maturation of ?-factor, transporters of a-factor, pheromone receptors, etc.) and a potential peptide modulator of the surrogate, in such a manner that the inhibition or activation of the surrogate affects a screenable or selectable trait of the yeast cells. Various additional features improve the signal-to-noise ratio of the screening/selection system.
    Type: Grant
    Filed: February 26, 1999
    Date of Patent: June 26, 2007
    Assignee: Cadus Technologies, Inc.
    Inventors: Dana M. Fowlkes, Jim Broach, John Manfredi, Christine Klein, Andrew J. Murphy, Jeremy Paul, Joshua Trueheart
  • Patent number: 7122305
    Abstract: The present invention makes available a rapid, effective assay for screening and identifying pharmaceutically effective compounds that specifically interact with and modulate the activity of a cellular receptor or ion channel. The subject assay enables rapid screening of large numbers of polypeptides in a library to identifying those polypeptides which induce or antagonize receptor bioactivity. The subject assay is particularly amenable for identifying surrogate ligands for orphan receptors.
    Type: Grant
    Filed: December 21, 2000
    Date of Patent: October 17, 2006
    Assignee: Cadus Technologies, Inc.
    Inventors: Christine A. Klein, Andrew J. Murphy, Dana M. Fowlkes, James Broach, John Manfredi, Jeremy Paul, Joshua Trueheart
  • Publication number: 20050202403
    Abstract: The present invention pertains to novel yeast cells which are useful for the expression of heterologous G protein coupled receptors. The yeast cells of the present invention can be used in screening assays which can be used to screen for modulators of G protein coupled receptors. Specifically, the invention provides novel yeast cells which express a heterologous G protein coupled receptor and mutant and/or chimeric G protein subunit molecules which serve to functionally integrate the heterologous into the pheromone signaling pathway of the yeast cell. The invention also provides for the expression of heterologous G protein coupled receptors which are functionally integrated into the yeast cell membrane using a yeast a factor leader sequence. Drug discovery assays using the subject yeast cells are also provided.
    Type: Application
    Filed: October 15, 2004
    Publication date: September 15, 2005
    Applicant: Cadus Technologies, Inc.
    Inventors: Dana Fowlkes, James Broach, John Manfredi, Jeremy Paul, Joshua Trueheart, Christine Klein, Andrew Murphy
  • Patent number: 6911311
    Abstract: An in vitro method for detecting protein-protein interactions is provided, in which two fusion proteins are prepared and allowed to interact with each other in a substantially cell free environment. The interaction between the two fusion proteins leads to protein trans-splicing, generating an active and detectable reporter.
    Type: Grant
    Filed: January 4, 2002
    Date of Patent: June 28, 2005
    Assignee: Myriad Genetics, Inc.
    Inventor: John Manfredi